

CURRICULUM VITAE (Rev. 8/20/2002)

Name: **MARVIN CHRIS MEYER**

Address: (b)(6)

Educational Background:

Undergraduate Training: Wayne State University, Detroit, Michigan
B.S. in Pharmacy

Graduate Training: Wayne State University, Detroit, Michigan
M.S. Major: Pharmaceutics

State University of New York at Buffalo,
Buffalo, New York
Ph.D. Major: Pharmaceutics

Financial Support for Graduate Training:

Wayne State University: Undergraduate Teaching Assistant, 1963-1964

American Foundation for Pharmaceutical
Education Fellowship, 1964-1965

S.U.N.Y. at Buffalo: American Foundation for Pharmaceutical
Education Fellowship, 1965-1966

National Institutes of Health, Predoctoral
Fellow, 1966-1968

Professional Experience:

Deaconess Hospital
Detroit, Michigan

Intern/Pharmacist, 1960-1964

Department of Pharmaceutics
College of Pharmacy
University of Tennessee
Center for the Health Sciences
Memphis, Tennessee

Assistant Professor
January 1969-December 1971

Division of Drug Metabolism
and Biopharmaceutics
Department of Medicinal Chemistry
College of Pharmacy
University of Tennessee
Center for the Health Sciences
Memphis, Tennessee

Director of the Division, Assistant
Professor of Medicinal Chemistry
and Pharmaceutics
January-June 1972

Director of the Division, Associate Professor
of Medicinal Chemistry and Biopharmaceutics
July 1972-June 1976

Director of the Division, Professor
of Medicinal Chemistry and Biopharmaceutics
July 1976-June 1978

Division of Biopharmaceutics
and Pharmacokinetics
Department of Pharmaceutics
College of Pharmacy
University of Tennessee
Center for the Health Sciences
Memphis, Tennessee

Vice Chairman, Division Director
and Professor of Pharmaceutics
July 1978-June 1983

Director, Graduate and Research
Programs - College of Pharmacy
July 1980-June 1981

Assistant Dean for Graduate and
Research Programs
July 1981-June 1983

Associate Dean for Graduate and
Research Programs
February 1984-

Acting Chairman, Dept. of Pharmaceutics
July 1990-May 1991

Chairman, Department of Pharmaceutics
May 1991

Acting Chairman, Dept. of Medicinal Chemistry
October 1990-October 1991

Chairman, Department of Pharmaceutical Sciences
Oct. 1991

Foreign Language: (b)(6)

Memberships:

Honor Societies:

Rho Chi, National Pharmacy Honor Society

Omicron Delta Kappa - National Men's Honorary Leadership Society

(b)(6)

Sigma Xi - National Research Honor Society

Phi Lambda Sigma - National Pharmacy Leadership Society

Professional and Scientific Organizations:

American Pharmaceutical Association

American Association of Colleges of Pharmacy

Phi Delta Chi - Professional Pharmaceutical Society

Memphis Area Society of Hospital Pharmacists

Tennessee Pharmaceutical Association

Memphis and Shelby County Pharmaceutical Society

Associate Fellow - American College of Apothecaries

Academy of Pharmaceutical Sciences

American Association of Pharmaceutical Scientists

Biographical Recognition:

Outstanding Educators of America

American Men and Women of Science

(b)(6)

International Who's Who in Education

Who's Who in Frontier Science and Technology

Honors and Awards:

American Foundation for Pharmaceutical Education Fellow (1963-1966)

Public Health Service Fellow (1966-1968)

Donnley Award, Phi Delta Chi Award, Rexall Award, Medical Arts Award,
(Wayne State University)

Mead Johnson Undergraduate Research Award at the University of Tennessee (1970)

University of Tennessee National Alumni Association Public Service Award (1988)

Teacher of the Year, Pharmacy Class of 1992

Fellow, American Association of Pharmaceutical Scientists (1990)

Visiting Professor, College of Pharmacy, University of Clermont-Ferrand,
France, May 1992

Appointed Member, FDA Advisory Committee for Pharmaceutical Sciences
May 31, 2001-October 31, 2004.

Major University Appointments and Activities:

(b)(6)

Elected Member, Academic Standing & Promotions Review Committee,
UT College of Pharmacy (1974-1975)

Member, UT Advisory Committee for the Position of Dean of the College
of Pharmacy (1975)

Chairman, Department of Pharmaceutics Graduate Admissions
Committee (1978-present)

Chairman, College of Pharmacy Promotion and Tenure Committee

Member, UTCHS Graduate Program Review Committee (1978-1980)

Member, UTCHS Search Committee for Dean of the Graduate School (1980)

Member, President's Advisory Committee for Selection of a Chancellor (1980)

Member, UTCHS Research Committee (1980-present)

Member, UTCHS Graduate Council (1980-present)

Chairman, College of Pharmacy Graduate/Research Council (1980-present)

Member, UTCHS Graduate-Research Administration Council (1982)

Member, UTCHS Academic Affairs Council (1983)

Member, UT, Memphis Search Committee, Van Vleet Professor of
Medicinal Chemistry (1986)

Member, UT, Memphis Search Committee, Graduate School Dean (1986-1987)

Member, College of Pharmacy Executive Advisory Committee (1983-Present)

Chairman, Search Committee for Graduate School Associate Dean
for Research (1988)

Chairman, Search Committee for the Van Vleet Endowed Chair (1991-1992)

Ancillary Appointments and Activities:

Consultant for Palmer Chemical Company (1970-1971)

Scientific Review Panelist, American Pharmaceutical Association Drug
Interactions Project (1972)

Consultant for Bioavailability Studies, Veterans Administration (1972)

(b)(6)

Consultant for Drug Abuse Testing Programs, National Collegiate Athletic Association (1973)

Ancillary Appointments and Activities (cont.d)

Expert for the United States Food and Drug Administration in Drug Bioavailability (1973-1976)

Participant in Workshop on Biochemical Approaches to Clinical Pharmacology, University of California San Francisco, Sponsored by National Academy of Sciences, Division of Medical Science (1973)

Consultant for Berlex Laboratories, Inc., Cedar Knolls, New Jersey (1975-1976)
Member, American Society of Hospital Pharmacists Review Panel, FDA Class Labeling Project (1976)

Consultant, Bell Pharmacal, Greenville, South Carolina (1976-1980)

Reviewer, NIH, National Institute of Child Health and Human Development (1978)

Visiting Professor, Roche Laboratories, Pharmaceutical Manufacturers Association Faculty Visitation Program (May 29-June 9, 1978)

Invited Lecturer for Food and Drug Administration Course in Biopharmaceutics and Pharmacokinetics, Rockville, Maryland (May 1-3, 1979; May 13-16, 1980; June 1-4, 1981)

Expert Witness for the U.S. Food and Drug Administration (Sept. 1980)

Consultant, Pfizer Pharmaceuticals, Inc. (1980-1981)

Consultant, Cord Laboratories, Inc. (1980-1987)

Consultant, Key Pharmaceuticals (1981-1988)

Consultant, Purdue Frederick (1982-1984)

Consultant, DuPont, Inc. (1982-1983)

Consultant, Pennwalt Corporation (1982-1983)

Consultant, PharmaKinetic Laboratories, Inc. (1982-1983)

Consultant, Forrest Laboratories, Inc. (1984)

Consultant, Ciba-Geigy (1984-1986)

Expert Witness, U.S. District Court, N.Y. (1984, 1985)

Consultant, International Drug Registration (1983-1987)

Consultant, Glaxo, Inc. (1983-1986)

Consultant, Sandoz Pharmaceuticals (1983-1986)

Consultant, Barr Laboratories (1984-1985, 1996-)

Biopharmaceutics Short Course Director, U.S. Food and Drug Administration,
Rockville, Maryland, June 25-28, 1985

Ancillary Appointments and Activities (cont.d)

Member, Academy of Pharmaceutical Sciences, Dissolution Report
Editorial Committee (1985)

Member, AACP Volwiler Award Committee (1986, 1987)

External Examiner, University of Tasmania (1985)

Consultant, Sidmak Laboratories (1987-present)

Member, Editorial Review Board, "Applied Pharmacokinetics," W.E. Evans,
J. J. Schentag and William J. Jusko, Applied Therapeutics, Inc., Spokane, WA,
2nd Edition, 1986.

Member, Technical Advisory Board, Duramed Pharmaceuticals Cincinnati, OH
(1986-1987)

Member, American Association of Pharmaceutical Scientists, Task Force on
Bioequivalence, Washington, D.C. September 11, 1986

Consultant, Vitarine Pharmaceuticals, Inc. (1986-1992)

Consultant, Eon Laboratories (1992-)

Member, AACP Volwiler Research Achievement Award Committee (1986, 1987)

Member, Drug Standards Consultance Panel, The Upjohn Co. (1986-1990)

Member, External Board of Advisors, Pharmacokinetics Laboratory, Inc. (1987)

Member, Regulations and Science Policy Committee, American Association of
Pharmaceutical Scientists (1988)

Consultant, FDA office of Orphan Products (1988, 1989, 1990)

Coordinator and Moderator, A.Ph.A. Scientific Symposium, Bethesda, Maryland,
Sept. 16-17, 1988

Consultant, Schering Corp. (1988)

Consultant, Wyeth-Ayerst (1988)

Consultant, Reid-Rowell, Inc. (1989)

Consultant, Guidelines, Inc. (1989)

Consultant, UDL Laboratories (1990)

Consultant, Biocraft Laboratories (1990)

Consultant, Ciba-Geigy Canada (1990, 1991-1994)

Consultant, MOVA Pharmaceuticals (1990, 1992)

Ancillary Appointments and Activities (cont.d):

Consultant, NAPM (1990)

Consultant, Upjohn (1990, 1991)

Consultant, Searle Pharmaceuticals (1992)

Served as the course director for a course in biopharmaceutics & pharmacokinetics, presented to staff scientists in the FDA's Office of New Animal Drug Evaluation, Center for Veterinary Medicine, Rockville, Maryland, April 8-10, 1992

Consultant, Lemmon Pharmaceuticals (1992)

Consultant, Chelsea Laboratories (1994-)

Consultant, TimeRx Technologies (1994-)

Consultant, Copley Pharmaceuticals (1994-95)

Consultant, Zenith Laboratories (1994)

Selection Committee, AAPS New Investigator Grant (1996)

Expert - James V. Ball, Attorney, Memphis, TN (1997)

Consultant, Schein Laboratories (1999-2000)

Consultant, Pharmacia (1999-2000)

Consultant, Aventis (1999-2000)

Consultant, Blancett Pharmaceuticals (1999-2000)

Consultant, Advanced Care Products (1999-2000)

Consultant (2000-2001) for: Penwest (Scientific Advisory Board); Delsys (Scientific Advisory Board); Sidmak; Pharmacia; Andrx; Purepac; Endo; Banner Pharmacap; Blancett Pharmacal; Aventis; Barr Laboratories; Advanced Care Products; Schein/Watson

Consultant (2001-2002) for Penwest Scientific Advisory Board, Sidmak, Pharmacia, Barr Labs, Elite Laboratories, Morgan, Lewis & Bockius, Allied Clinical Research,

Member, FDA's Pharmaceutical Sciences Advisory Committee (2001-2004)

Journal Reviewer:

Pharmaceutical Research
Journal of Pharmaceutical Sciences
American Journal of Pharmaceutical Education
Journal of Pharmacokinetics and Biopharmaceutics
Journal of Pharmaceutical Sci. (The Pharmaceutical Soc. Egypt)
Biopharmaceutics and Drug Disposition
International Journal of Pharmaceutics
Medical Letter
Archives of Internal Medicine
Chest
Clinical Pharmacy
Journal of the American Medical Association
Drug Intelligence and Clinical Pharmacy
Journal of Pharmacy Teaching

Courses Taught at the University of Tennessee:

Undergraduate: Pharmaceutical Technology
 Biopharmaceutics
Graduate: Physico-Chemical Principles Pharmaceutical Systems
 Kinetics of Pharmaceutical Systems
 Advanced Pharmacokinetics

Invited Presentations:

Southern School of Pharmacy, Mercer University, Atlanta, Georgia, January 16, 1971

Medicaid Title XIX Pharmacy Administrator's Seminar, Atlanta, Georgia,
November 16, 1972

College of Pharmacy, University of Nebraska, Lincoln, Nebraska, November 20, 1972

Annual Meeting, Memphis Area Society of Hospital Pharmacists, Memphis,
Tennessee, January 13, 1973

National Science Foundation Seminar, Christian Brothers College, Memphis, Tennessee, March 17, 1973

National Center for Toxicological Research, Pine Bluff, Arkansas, December 13, 1973

Memphis and Shelby County Pharmaceutical Society, Memphis, Tennessee, January 15, 1974

Invited Presentations:

American Association for the Advancement of Science, San Francisco, California,
February 27, 1974

Southern Association of Medicaid Administrators, Austin, Texas, March 26, 1974

Capitol City Representatives Seminar, Sponsored by Roche Laboratories, Atlanta, Georgia, June 17, 1974

World Health Information Service Symposium on "Revolution in Health Care",
Columbia, South Carolina, September 30, 1974

(b)(6)

Tennessee Psychiatric Hospital and Research Institute, Memphis, Tennessee,
January 26, 1975

Eli Lilly Company, Indianapolis, Indiana, February 5, 1975

University of South Carolina, Continuing Education Program on Psychotherapeutic Drugs, Columbia,
South Carolina, February 26, 1975

Continuing Education Caribbean Cruise, Sponsored by ACA and Pharmasea,
March 8-15, 1975

Testimony before the Tennessee House Sub-Committee for Consumer Affairs, Nashville, Tennessee,
April 8, 1975

Association of Medicaid Pharmacy Administrators, Nashville, Tennessee,
September 24, 1975

District Ten Pharmaceutical Association, Columbia, Tennessee, October 23, 1975

District Six Pharmaceutical Association, Cookeville, Tennessee, January 28, 1976

WHBQ-TV (ABC) UTCHS Health Care Perspectives Television Program,
April 11, 1976

Middle Tennessee Society of Hospital Pharmacists, Nashville, Tennessee,

April 15, 1976

Diamond Shamrock Corporation, Painsville, Ohio, November 2, 1976

Bell Pharmacal, Greenville, South Carolina, November 9, 1976

Visiting Professor of the Multinational Project on Chemistry of the OAS Regional Scientific and Technological Development Program, University of Panama, November 13-27, 1976

Bell Pharmacal, Greenville, South Carolina, November 6, 1976; January 12, March 28 and July 12, 1977

Symposium participant at the 37th International Congress of Pharmaceutical Sciences, The Hague, The Netherlands, September 6, 1977

UTCHS College of Pharmacy Continuing Education Program, Nashville, Tennessee, January 22, 1978

University of Kentucky, Annual Kostenbauder Postgraduate Research Conference, October 20, 1978

Food and Drug Administration, Division of Biopharmaceutics, Research Seminar, Washington, D.C., February 15, 1979

Bell Pharmacal, Greenville, South Carolina, March 15, and April 26, 1979

(b)(6)

Super X Pharmacists? Regional Meeting, Fort Lauderdale, Florida, July 31, 1979

College of Pharmacy, University of Arkansas, Little Rock, Arkansas, November 1, 1979

Association of Medicaid Pharmacy Administrators, Chattanooga, Tennessee, October 23, 1979

19th Annual International Industrial Pharmacy Conference, Austin, Texas, February 28, 1980

Berlex Laboratories, Cedar Knolls, New Jersey, May 6, 1980

Veterans Administration Southeastern Regional Medical Education Center Program, Memphis, Tennessee, August 27, 1980

Middle Tennessee Society of Pharmacists, Nashville, Tennessee, October 23, 1990

Third Annual Pharmaceutical Development Conference, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, March 8-11, 1981

Roundtable Discussion of Graduate Education in the Pharmaceutical Sciences, A.Ph.A. Meeting, Las Vegas, NV, April 27, 1982

Pharmaceutical Technology Conference, New York, NY, September 22, 1982

Roundtable Discussion on Theophylline, American Academy of Allergy and Immunology, Hollywood, Florida, March 20, 1983

UTCHS, TSHP and Dista Products Company Continuing Education Program, "Scientific and Clinical Principles of Pharmacokinetics", Memphis, Tennessee, September 9, 1983

Tennessee Society of Physicians Assistants Annual Conference, Nashville, Tennessee, September 16, 1983

UTCHS and Sandoz Pharmaceuticals Continuing Education Program, "Choice of Antipsychotic Drugs", Tri-Cities (October 9, 1983), Chattanooga (October 30, 1983) and Jackson, Tennessee (November 20, 1983)

Academy of Pharmaceutical Sciences Symposium, "Critique of the USP Policy on Modified Release Dosage Forms", Miami, Florida, November 15, 1983

New York Academy of Sciences Symposium, "A New Approach to the Management of Opioid Dependence: Naltrexone, and Oral Antagonist", New York, New York, November 7, 1983

State University of New York, College of Pharmacy Symposium Honoring Dean Daniel Murray, Buffalo, New York, April 28, 1984

Upjohn Company, Kalamazoo, Michigan, May 10, 1984

26th Annual National Industrial Pharmaceutical Research Conference, University of Wisconsin, Lake Delton, Wisconsin, June 12, 1984

Pharmaceutical Society, Sheffield, Alabama, February 10, 1985

Black Pharmacists Society, Memphis, Tennessee, May 19, 1985

Ciba-Geigy, Pharmaceuticals Division, Summit, New Jersey, May 30, 1985

Kentucky Third District Pharmaceutical Society, Bowling Green, Kentucky, September 12, 1985

Rutherford County Pharmaceutical Society, Murfreesboro, Tennessee, September 13, 1985

Chattanooga-Hamilton County Pharmaceutical Society, Chattanooga, Tennessee, September 15, 1985

Drug Information Association, Workshop on Controlled Release Dosage Forms, Washington, D.C., September 30, 1985

Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, December 4-5, 1985

Memphis and Shelby County Pharmaceutical Society, Memphis, Tennessee, January 14, 1986

Hahneman University Conference on Bioequivalence, Philadelphia, Pennsylvania, February 10, 1986

Northwest Mississippi Regional Medical Center, Clarksdale, Mississippi, February 18, 1986

International Industrial Pharmacy Conference, University of Texas at Austin, Montgomery, Texas, February 23-27, 1986

Dickson Area Pharmaceutical and Medical Societies, Dickson, Tennessee, April 3, 1986

Tennessee Pharmaceutical Association, Nashville, TN, June 9, 1986

Tufts University "Postmarketing Surveillance Program", Boston, MA, July 9-10, 1986

American College of Apothecaries Annual Meeting, Toronto, Canada, August 17, 1986

Pfizer Pharmaceuticals, New York, NY, September 2, 1986

Hahnemann University, Bioequivalence Program, Washington, D.C., September 29, 1986

Family Medical Center Healthplex Baptist Hospital, Memphis, TN, October 2, 1986

Gulf Coast Pharmaceutical Assoc., Fort Myers, Florida, October 8, 1986

First District Pharmaceutical Association, Johnson City, TN, November 23, 1986

Vanderbilt Hospital, Nashville, Tennessee, January 15, 1987

Oral Controlled Release Dosage Forms Symposium, Nortec Development Associates, Woodcliff Lake, N.J. March 11, 1987

UT Alumni Weekend Symposium, Memphis, TN. Sept. 18, 1987

Rocky Mountain Drug Consultation Center Symposium, Denver, Co., Nov. 9, 1987

Memphis and Shelby County Pharmaceutical Society, Memphis, TN, Sept. 14, 1988

Moderator - APhA Scientific Symposium on Bioequivalence, Bethesda, Maryland, Sept. 16-17, 1988

Memphis & Shelby Co. Pharmaceutical Soc., "Dosage Forms of the Future", Memphis, Tennessee, Sept. 14, 1988

St. Mary's Medical Center, "Novel Drug Delivery Systems", Knoxville, Tennessee, Oct. 25, 1988

Methodist Medical Center, "Novel Drug Delivery Systems", Knoxville, Tennessee, Oct. 25, 1988

Glaxo Symposium, "Clinical Pharmacokinetics of Albuterol Controlled-Release Dosage Forms", Laguna Niguel, California, April 28, 1989

Greater Knoxville Epilepsy Foundation Annual Meeting, Knoxville, TN, September 9, 1989

SynerMed Roundtable Discussion of Generic Drug Products, Los Angeles, CA, September 18, 1989

Bio International '89 Symposium, Toronto, Canada, October 1-4, 1989

American Association of Pharmaceutical Scientists, Panel Moderator, Atlanta, GA, October 22-26, 1989

FDA Advisory Committee Meeting on Conjugated Estrogens, Rockville, MD., May 3, 1990

AAPS Regional Meeting, Chicago, Ill., May 14, 1990

Biocraft Laboratories sponsored round-table discussion of generic drugs,

Fair Lawn, NJ, September 17, 1990

Wisconsin Pharmacists Association Annual Meeting, Oconomowoc, WI.,
September 22, 1990

Conference on Bioequivalence, McGill University, Montreal Canada, March 28-31, 1991

University of Montreal Symposium, Montreal Canada, April 21-24, 1991

American Society for Hospital Pharmacists Annual Meeting, Symposium on
Antiepileptic Drugs and Pharmacy Practice, New Orleans, December 10, 1991

American Pharmaceutical Association Annual Meeting, San Diego, CA, Symposium
on Variable Affecting Drug Product Efficacy, March 14, 1992

University of Clermont-Ferrand Annual Industry-Academic Symposium, Clermont-
Ferrand France, May 13-15, 1992

SynerMed Roundtable Discussion on Generic Drugs, Arlington, VA,
July 25, 1992

Ciba-Geigy Pharmaceuticals, Ardsley, NY, July 27, 1992

SynerMed Roundtable Discussion on Anticonvulsant Drug Therapy,
New York, October 27, 1992

Upjohn Company, Kalamazoo, Michigan, May 17, 1994

M. Meyer. "Current Scientific Issues Regarding BA/BE Studies: An Academic View."
DIA Workshop, Rockville, MD, Sept. 1994

M. Meyer, "FDA Sponsored Research at the University of Tennessee", Food and Drug
Administration, Rockville, MD, Nov. 17, 1994

M. Meyer, "Overview of Research in the Pharmaceutical Sciences", Hoechst Research
Day, University of Tennessee, Knoxville, TN, Feb. 1995

M. Meyer. "Highly Variable Drugs", AAPS/FDA Workshop, Crystal City VA, March 1995

Meyer, M.C., Use of Special Populations in Phase I Trials, AAPS Open Session on
Special Populations, Seattle, WA, October 29, 1996

Meyer, M.C., In Vitro-In Vivo Examples, AAPS/FDA/CRS Workshop "Scientific
Foundations for Regulating Drug Product Quality", Crystal City, VA, April 15, 1997

Meyer, M.C. Bioequivalence Issues: Past, Present and Future, College of
Pharmacy, University of Arkansas, Little Rock, AR, April 25, 1997

Meyer, M.C. FDA Sponsored Bioequivalence Studies at the University of Tennessee,
Food and Drug Administration, Rockville, MD, August 18, 1997

Hard and Soft Gelatin Capsules: Issues, Research and Outcome: Bioequivalence
Studies, AAPS Invited Podium Session, Boston, MA, Nov. 5, 1997

FDA Advisory Committee Meeting on Narrow Therapeutic Index Drugs, Rockville, MD.,
December 11, 1997

Minnesota Drug Formulary Commission, Minneapolis, MN August 7, 1998.

Illinois Legislative Conference Committee, Indianapolis, IN, Sept. 2, 1998

Grand Rounds, Abington PA Memorial Hospital, May 18, 1999

Ohio Senate Committee on Health Care, Columbus OH, May 19, 1999

"Perspectives and Points of View - Pharmaceutical Sciences", AAPS International Workshop on Individual Bioequivalence, Montreal, Canada, September 1999

Presentation to the Florida Senate Committee on Generic Drug Formularies, Nov. 3, 1999

"Why Failed Bioequivalence Studies - Science and Technical Issues", Symposium at AAPS Meeting, New Orleans, LA, Nov. 14, 1999

Invited Presentations (cont.d):

"Research Programs at the University of Tennessee College of Pharmacy", at the National Center for Toxicology Research, Jefferson, Arkansas, April 4, 2000

FDA/AAPS Workshop - Biopharmaceutics in the New Millennium, Washington, DC
September 13, 2000

Thesis and Dissertation:

M.S. - "The Interaction of Atropine with Kaolin"

Ph.D. - "The Binding of Drugs by Plasma Proteins"

Textbook:

1. "Complexation", Chapter 12, p. 558-591. In E.W. Martin, Ed., Dispensing of Medication, 7th Ed., Mack Publishing Co., Easton, Pa., 1971.
2. "Medication Orders," Chapter 1. In E.W. Martin, Ed., Dispensing of Medication, 8th Ed., Mack Publishing Co., Easton, Pa., 1987.
3. "Complexation", Chapter 14, Remington's Pharmaceutical Sciences-17th Edition, Mack Publishing Co., Easton, Pa., 1985.
4. "Bioavailability of Drugs" and "Bioequivalence", Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. Boylan, eds. Marcel Dekker, Inc., Vol. 1, P. 477-493(1988).
5. "Bioavailability of Transdermal and Topical Dosage Forms", in Bioavailability and Bioequivalence, ed. P. Welling, F. Tse and S. Dighe, Marcel Dekker, N.Y., P. 169-223 (1991).
6. "IVIVC Examples", in Scientific Foundations for Regulating Drug Product Quality, ed. G. Amidon, J. Robinson and R. Williams, AAPS Press Alexandria, VA, P. 329-345, October 1997.
7. Dalton, JT and Meyer MC. "Bioavailability of Drugs" and "Bioequivalence", Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. Boylan, eds. Marcel Dekker, Inc., (In press, 2000)

Publications:

1. "Interactions of Xanthine Derivatives with Bovine Serum Albumin III - Inhibition of Binding". M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 57, 245 (1968).

2. "The Binding of Drugs by Plasma Proteins". M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 57, 895 (1968).
3. "A Novel Method for Studying Protein Binding". M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 57, 1627 (1968).
4. "The Pharmacist and Generic Equivalence". M.C. Meyer, Tennessee Pharmacist, 5, 6 (1969)
5. "Dynamic Dialysis as a Method for Studying Protein Binding I. - Factors Affecting the Kinetics of Dialysis through a Cellophane Membrane". M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 59, 33 (1970).
6. "Dynamic Dialysis as a Method for Studying Protein Binding II. - Evaluation of the Method with a number of Binding Systems." M.C. Meyer and D.E. Guttman, J. Pharm. Sci., 59, 39 (1970).
7. "Theoretical Drug Levels During Multiple Dosing in a Two-Compartment Open Model". M.C. Meyer, Arch. Int. Pharmacodyn. 193, 141 (1971).
8. "Permeation of Solutes Through Polyethylene I. The Effects of Structure on Permeability of a Series of Aniline Derivatives". D.G. Serota, M.C. Meyer and J. Autian, J. Pharm. Sci., 61, 416 (1972).
9. "Permeation of Aromatic Organic Compounds from Aqueous Solutions Through Polyethylene". K. Nasim, M.C. Meyer and J. Autian, J. Pharm. Sci., 61, 1775 (1972).
10. "Bioavailability of Fourteen Nitrofurantoin Products". M.C. Meyer, G.W.A. Slywka, R.E. Dann and P.L. Whyatt, J. Pharm. Sci., 63, 1693 (1974).
11. "The Bioavailability of Sixteen Tetracycline Products". M.C. Meyer, R.E. Dann, P.L. Whyatt, and G.W.A. Slywka, J. Pharmacokin. Biopharm. 2, 287 (1974).
12. "The Role of State Formularies in Providing Quality Drug Products Economically". M.C. Meyer, H. Bates, R.G. Swift, J.A.Ph.A., NS 14, 663 (1974).
13. "Rapid, Precise Turbidimetric Assay for Low Levels of Ampicillin in Serum After Single Dose Oral Administration". P.L. Whyatt, R.E. Dann, G.W.A. Slywka and M.C. Meyer, Antimicrobial Agents and Chemotherapy, 6, 811 (1974).
14. "The Tennessee Drug Quality Assurance program". P.L. Whyatt, G.W.A. Slywka, A.P. Melikian, H.E. Bates and M.C. Meyer, Tennessee Pharmacist, 11, 12 (1975).
15. "Inequivalency of Nitrofurantoin Products". M.C. Meyer, G.W.A. Slywka, P.L. Whyatt and A.P. Melikian, J.A.M.A., 232, 1009 (1975).
16. "Propoxyphene Bioavailability: An Evaluation of Ten Products". G.W.A. Slywka, A.P. Melikian, P.L. Whyatt and M.C. Meyer, J. Clin. Pharmacol., 15, 598 (1975).
17. "The Binding of Salicylate and Sulfathiazole by Whole Blood Constituents". C. Cruze and M.C. Meyer, J. Pharm. Sci., 65, 33 (1976).
18. "Hydrochlorothiazide Bioavailability: An Evaluation of Thirteen Products". M.C. Meyer, A.P. Melikian, P.L. Whyatt and G.W.A. Slywka, Curr. Ther. Res., 17, 570 (1975).
19. "Folic Acid Administration to Chronic Hemodialysis Patients". V.A. Skoutakis, S.R. Acchiardo, M.C. Meyer and F.E. Hatch, Clin. Pharmacol. Ther., 18, 200 (1975).
20. "The Bioavailability of Seventeen Ampicillin Products". P.L. Whyatt, G.W.A. Slywka, A.P. Melikian and M.C. Meyer, J. Pharm. Sci., 65, 652 (1976).

21. "Hydrochlorothiazide Bioavailability Monograph". M.C. Meyer and P.L. Whyatt, J.A.Ph.A., NS 16, 47 (1976).
22. "Bioavailability of 11 Sulfisoxazole Products in Humans". G.W.A. Slywka, A.P. Melikian, A.B. Straughn, P.L. Whyatt and M.C. Meyer, J. Pharm. Sci., 65, 1494 (1976).
23. "The Relationship of Price to Bioavailability for Four Multiple Source Drug Products". G.W.A. Slywka, M.R. Ryan, A.P. Melikian, M.C. Meyer, H.E. Bates and P.L. Whyatt, J.A. Ph.A., NS 17, 30 (1977).
24. "Bioavailability of Eleven Phenytoin Products". A.P. Melikian, A.B. Straughn, G.W.A. Slywka, P.L. Whyatt and M.C. Meyer, J. Pharmacokin. Biopharm., 5, 133 (1977).
25. "Drug Interactions Involving Aminosalicilic Acid". M.C. Meyer, T.H. Self and A.B. Straughn, Reviews on Drug Interactions, 2, 107 (1977).
26. "Estimations of Drug Dosing Regimens with A Pharmacokinetic Slide Rule". A.B. Straughn, C.A. Cruze and M.C. Meyer, Am. J. Hosp. Pharm., 34, 197 (1977).
27. "Meprobamate Bioavailability Monograph". M.C. Meyer and A.B. Straughn, J.A.Ph.A., 17, 173 (1977).
28. "The Role of Drug Equivalency and Bioavailability in Formulary Determination". M.C. Meyer, Revolution in Health Care, 1, 33 (1975).
29. "Factors Affecting the Bioavailability of Chlorothiazide in Man". M.C. Meyer and A.B. Straughn, Curr. Ther. Res., 22, 573-582 (1977).
30. "The Relative Bioavailability of Meprobamate Tablets in Man". M.C. Meyer, A.P. Melikian and A.B. Straughn, J. Pharm. Sci., 67, 1290-1292 (1978).
31. "The Bioavailability of Sulfadiazine Solutions, Suspensions and Tablets in Man". M.C. Meyer, A.B. Straughn, G. Ramachander, J.C. Cavagnol and A.F.B. Mabadeje, J. Pharm. Sci., 67, 1659-1661 (1978).
32. "The Influence of Dosage Form on Papaverine Bioavailability". M.C. Meyer, R. Gollamudi and A.B. Straughn, J. Clin. Pharmacol., 19, 435 (1979).
33. "Simultaneous Determination of Methenamine and Formaldehyde in the Urine of Humans After Methenamine Administration". R. Gollamudi, M.C. Meyer and A.B. Straughn, Biopharm. Drug Disposition, 1, 27 (1979).
34. "The Bioavailability of Chlorothiazide Tablets in Man". A.B. Straughn, A.P. Melikian and M.C. Meyer, J. Pharm. Sci., 68, 1099 (1979).
35. "A HPLC Assay for the Determination of Griseofulvin in Plasma". M.C. Meyer and G. Raghaw, J. Pharm. Sci., 68, 1127 (1979).
36. "A Multiple-Dose Study of Sustained-Release Theophylline and Aminophylline". M.C. Meyer, A.B. Straughn and P. Lieberman, Chest, 78, 300 (1980).
37. "The Bioavailability of Microsize and Ultramicrosize Griseofulvin Product in Man". A.B. Straughn, M.C. Meyer, G. Raghaw and K. Rotenberg, J. Pharmacokin. Biopharm., 8, 347 (1980).
38. "Evaluation of Enzyme Immunoassay, Radioassay, and Radioimmunoassay of

- Serum Methotrexate, with Liquid Chromatography as a Standard". R.G. Buice, W.E. Evans, J. Karas, C.A. Nicholas III, P. Sidhu, A.B. Straughn, M.C. Meyer and W.R. Crom, Clin. Chem., 26, 1902 (1980).
39. "Pharmacokinetics of Propylthiouracil Upon P. O. Administration in Man". H.P. Ringhand, W.A. Ritschel, M.C. Meyer, A.B. Straughn and T. Hardt, Intl. J. Clin. Pharmacol. Ther. Toxicol., 18, 3011 (1980).
 40. "Urinary Excretion of Methenamine and Formaldehyde: An Evaluation of Ten Methenamine Products in Man". R. Gollamudi, A.B. Straughn and M.C. Meyer, J. Pharm. Sci., 70, 596 (1981).
 41. "The Determination of Trichlormethiazide in Human Plasma and Urine by HPLC". M.C. Meyer and P.T.R. Hwang, J. Chromatogr., 223, 466-472 (1981).
 42. "HPLC Assay of Tolbutamide and Carboxytolbutamide in Human Plasma". G. Raghaw and M.C. Meyer, J. Pharm. Sci., 70 1166-1168 (1981).
 43. "In Vivo-In Vitro Correlations with the Sartorius Dissolution Simulator I: Methenamine, Nitrofurantoin and Chlorothiazide". M.K.T. Yau and M.C. Meyer, J. Pharm. Sci., 70, 1017-1024 (1981).
 44. "Pharmacokinetics of Trichlormethiazide in Hypertensive Patients with Normal or Comprised Renal Function." I.S. Sketris, V.A. Skoutakis, S.R. Acchiardo and M.C. Meyer, Europ. J. Clin. Pharmacol., 20, 453 (1981).
 45. "HPLC Determination of Benzthiazide in Biologic Material." M.C. Meyer, P. Hwang, A.B. Straughn and K. Rotenberg, Biopharm. Drug Disposit., 3, 109 (1982).
 46. "Serious Bioavailability Problems with a Generic Prolonged-Release Quinidine Gluconate Product." M.C. Meyer, A.B. Straughn, P. Lieberman and J. Jacob, J. Clin. Pharmacol., 22, 131-134 (1982).
 47. "Relative Bioavailability of Acetazolamide Tablets." A.B. Straughn, R. Gollamudi and M.C. Meyer, Biopharm. Drug Disposit., 3, 75-82 (1982).
 48. "Hexoprenaline Pharmacokinetics in Pregnant and Nonpregnant Sheep." J. Lipshitz, M.K.T. Yau, M.C. Meyer, R.A. Aokas, A.L. Maduska, W.D. Whybrew, G.D. Anderson, J.C. Morrison and J. Schneider, Res. Commun. Chem. Pathol. Pharmacol., 34, 3-16 (1981).
 49. "Bioavailability of Propylthiouracil in Humans." H.P. Ringhand, W.A. Ritschel, M.C. Meyer, A.B. Straughn and B.E. Cabana, J. Pharm. Sci., 72, 1409-1412 (1983).
 50. "In Vivo-In Vitro Correlations with the Sartorius Dissolution Simulator II: Papaverine, Phenytoin and Sulfisoxazole." M.K.T. Yau and M.C. Meyer, J. Pharm. Sci., 72, 681-686 (1983).
 51. "High-Performance Liquid Chromatographic Micro-Assay for Cefoperazone in Human Plasma, Urine and CSF." P.T.R. Hwang and M.C. Meyer, J. Liq. Chromatogr., 6, 743-754 (1983).
 52. "Chloramphenicol Dosage and Pharmacokinetics in Infants and Children." G.J. Burckart, F.F. Barrett, R. Della Valle and M.C. Meyer, J. Clin. Pharmacol., 23, 210-216 (1983).
 53. "Nonlinear Ethotoin Kinetics." M.C. Meyer, B.J. Holcombe, G.J. Burckart, G. Raghaw and M.K. Yau, Clin. Pharmacol. Ther., 33, 329-334 (1983).

54. "Phenytoin, Part I: In Vitro/In Vivo Correlation for 100 mg Sodium Phenytoin Capsules." V.P. Shah, V.K. Prasad, T. Alston, B.E. Cabana, R.P. Gural and M.C. Meyer, J. Pharm. Sci., 72, 306-308 (1983).
55. "Importance of Media Selection in Establishment of In Vitro-In Vivo Relationships for Quinidine Gluconate." V.K. Prasad, V.P. Shah, P. Knight, H. Malinowski, B.E. Cabana and M.C. Meyer, Int. J. Pharmaceut., 13, 1-7 (1983).
56. "Absorption of Phenobarbital from Tablets and Elixir." M.C. Meyer, A.B. Straughn, G. Raghov, W.L. Schary and K.S. Rotenberg, J. Pharm. Sci., 73, 485-488 (1984).
57. "Plasma Levels of Ethavrine After Oral Administration to Humans." M.C. Meyer, G. Raghov and A.B. Straughn, Biopharm. Drug Disposit., 4, 401-404 (1983).
58. "Placental Transfer of Chloroquine in Pregnant Rabbits." A. Akintonwa and M.C. Meyer, Res. Commun. Chem. Path. Pharmacol., 40, 45(1983).
59. "Simultaneous Determination of Chloroquine and Desethylchloroquine in Blood, Plasma and Urine by High-Performance Liquid Chromatography." J. Liq. Chromatogr., 6, 1513-1522 (1983):.
60. "Bioequivalence, Dose-proportionality and Pharmacokinetics of Naltrexone After Oral Administration." M.C. Meyer, A.B. Straughn, M.L. Lo, W.L. Schary and C.C. Whitney, J. Clin. Psych., 45, 9-15 (1984)
61. "HPLC Determination of Ceftazidime in Serum, Urine, CSF and Peritoneal Dialysis Fluid." P.T.R. Hwang, P.G. Drexler and M.C. Meyer, J. Liq. Chromatogr., 7, 979-987 (1984).
62. "Bioavailability and Bioequivalence," M.C. Meyer, Ther. Drug Monitor Toxicol., 6, 1-7 (1984).
63. "A Chronopharmacokinetic Model for Sustained-Release Formulations," A.B. Straughn, M.C. Meyer, A. Golub and M.A. Gonzalez, Ann. Rev. Chronopharmacology, 1, 93-96 (1985).
64. "Administration of Theo-Dur Once Daily vs. Twice Daily," A.B. Straughn, M.C. Meyer, A.L. Golub, M.A. Gonzalez, In: Sustained Release Theophylline and Nocturnal Asthma, International Workshop, Burgenstock, Switzerland, Ed. A.F. Isles and P. von Wichert, Excerpta Medica, 1985, pp. 116-124.
65. "Bioavailability of Dyphylline and Dyphylline-guaifenesin Tablets in Humans," A.B. Straughn, G.C. Wood, G. Raghov and M.C. Meyer, J. Pharm. Sci., 74, 335-337 (1985).
66. "High-Performance Liquid Chromatographic Determination of Acetazolamide in Human Plasma," P.T.R. Hwang, J.R. Lang, G.C. Wood and M.C. Meyer, J. Liq. Chromatogr., 8, 1465-1473 (1985).
67. "Bioavailability of Seven Furosemide Tablets in Man," A.B. Straughn, G.C. Wood, G. Raghov and M.C. Meyer, Biopharm. Drug Disposit., 7, 113-120 (1986).
68. "Determination of Free Disopyramide Plasma Concentrations Using Ultrafiltration and EMIT," G. Raghov, M.C. Meyer and A.B. Straughn, Ther. Drug Monit., 7, 466-471 (1985).
69. "Nalmefene: Intravenous Safety and Kinetics of a New Opioid Antagonist," R. Dixon, J. Howes, J. Gentile, H. Hsu, J. Hsiao, D. Garg, D. Weidler, M.C. Meyer and R. Tuttle, Clin. Pharmacol. Ther., 39, 49-53 (1986).
70. "Dialyzability and Pharmacokinetics of Indomethacin in Adult Patients with End-Stage Renal Disease," V. A. Skoutakis, C. Carter, N.J. Wojciechowski, A.B. Straughn and M.C.

Meyer. Drug Intelligence and Clin. Pharm., 20, 956 (1986).

71. Monograph - "The Therapeutic Equivalence of Drug Products - A Second Look," M.C. Meyer, 99 pages, Public Planning Department, Hoffman-LaRoche, Inc., Nutley, NJ , 1985.
72. "Proceedings of the Food and Drug Administration Bioequivalence Hearing," September 29th-October 1, 1986, pages 89-116, 293-312 and 579-592.
73. "Influence of a Standard Meal on the Absorption of a Controlled-Release Pseudoephedrine Suspension," D.A. Graves, M.T. Wecker, M.C. Meyer, A.B. Straughn, L.P. Amsel, O.N. Hinsvark, A.E. Bhargava and K.S. Rotenberg, Biopharm. and Drug Disposit., 9, 267-272 (1988).
74. "Bioavailability of a Controlled-Release Albuterol Formulations for Twice-Daily Use," R.S. Sykes, M.E. Reese and M.C. Meyer, Biopharm. and Drug Disposit., 9, 551-556 (1988).
75. "Effect of Dose and Food on the Bioavailability of Cefuroxime Axetil," A. Finn, A. Straughn, M. Meyer and J. Chubb, Biopharm. and Drug Disposit., Vol. 8, 519-526 (1987).
76. "The Absorption of Sustained-Release Methylphenidate Formulations Compared to an Immediate-Release Formulation," K.S. Patrick, A.B. Straughn, E.J. Jarvi, G.R. Breese and M.C. Meyer, Biopharm. and Drug Dispos., 10, 165-172 (1989).
77. "A Circadian Rhythm in Theophylline Disposition During a Constant-Rate Intravenous Infusion of Aminophylline in the Dog," R. J. Rackley, A.B. Straughn, and M.C. Meyer, J. Pharm. Sci., 77, 658-661 (1988).
78. "Chronopharmacokinetic Simulation of a Circadian Rhythm in Theophylline Disposition During a Constant-Rate Intravenous Infusion of Aminophylline in the Dog," R. J. Rackley, A.B. Straughn, and M.C. Meyer, Ann. Review of Chronopharmacology, Vol. 5, 205-208 (1988).
79. "The Effect of pH on the In Vitro Dissolution and the In Vivo Absorption of Controlled-Release Theophylline in Dogs," V.I. Vashi and M.C. Meyer, J. Pharm. Sci. 77, 760-764 (1988).
80. "Gas Chromatographic-Mass Spectrometric Analysis of Plasma Oxybutynin Using a Deuterated Internal Standard," K.S. Patrick, J.S. Markowitz, E.J. Jarvi, A.B. Straughn and M.C. Meyer, J. Chromat. BioMed. Applic., 487, 91-98 (1988).
81. "In Vitro and In Vivo Evaluation of Seven 50mg and 100mg Nitrofurantoin Tablets," M.C. Meyer, G.C. Wood and A.B. Straughn, Biopharm. Drug Disposition, Vol. 10, 321-329 (1989).
82. "Gas Chromatographic-Mass Spectrometric Analysis of Plasma Nifedipine", K.S. Patrick, E.J. Jarvi, A.B. Straughn and M.C. Meyer, J. Chrom. (Biomed. App.) 495:123 (1989).
83. "Circadian Rhythms in Theophylline Disposition: Simulations and Observations in the Dog," R.J. Rackley, M.C. Meyer and A.B. Straughn, J. Pharm. Sci. 80:824-829 (1991).
84. "Generic Drug Products - The Tennessee Approach," M.C. Meyer, Tenn. Pharm., 26, 12-13 (1990).
85. "Scientific Basis of Bioavailability and Bioequivalence Testing," M.C. Meyer, Am. Pharm. 31:47-53 (1991).
86. "The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet," C.J. Betlach, A.B. Straughn, M.C. Meyer, M. Bialer, V.I. Vashi, P. Lieberman and M.A. Gonzalez, Pharm. Res.,

81:1516-1519 (1991).

87. "The Bioinequivalence of Carbamazepine Tablets with a History of Clinical Failures," M.C. Meyer, A.B. Straughn, E.J. Jarvi, G.C. Wood, F.R. Pelsor and V.P. Shah, Pharm. Res. 9, 1612-1616 (1992).
88. "Quantitative Determination of Cyclobenzaprine in Human Plasma by High Pressure Liquid Chromatography," P.T.R. Hwang, D.A. Young, A.B. Straughn and M.C. Meyer, J. Liq. Chromatography, 16,1163-1171 (1993).
89. "The Effect of Gastric pH on the Absorption of Controlled-Release Theophylline Dosage Forms in Humans," M.C. Meyer, A.B. Straughn, E.J. Jarvi, G.C. Wood, V.I. Vashi, P. Hepp and J. Hunt, Pharm. Res. 10, 1037-1045 (1993).
90. "Biopharmaceutical Factors in Seizure Control and Drug Toxicity," M.C. Meyer and A.B. Straughn, Am. J. Hosp. Pharm. 50, Suppl. 5, S17-S22 (1993) .
91. "Current Scientific Issues Regarding Bioavailability/Bioequivalence Studies: An Academic View," M.C. Meyer, Drug Information Journal, v. 29 (1995), Drug Information J. 29, 805-812 (1995).
92. "Relating Formulation Variables to In Vitro Dissolution Using an Artificial Neural Network," N.K. Ebube, T. McCall, Y. Chen and M.C. Meyer, Pharmaceutical Development and Technology, 2:225-232 (1997).
93. "IVIVC Examples", Meyer, M.C. in Scientific Foundations for Regulating Drug Product Quality, p. 353-371 (1997), AAPS Publ.
94. Meyer, MC, Straughn, AB, Mhatre, R, Shah, V, Williams, RL and Lesko, L. The Relative Bioavailability and In Vivo-In Vitro Correlations for Four Marketed Carbamazepine Tablets, Pharm. Res. 15:1787-1791 (1998).
95. Meyer, MC, Bolton, S and Chan, K. Generic Warfarin: Implications for Patient Care - Another View. Pharmacotherapy, 18:884-886 (1998)
96. Meyer, MC. Generic Drug Product Equivalence: Current Status. Am. J. Managed Care. 43:100-109 (1998).
97. Meyer, MC, Straughn, AB, Mhatre, RM, Shah, VP, Williams, RL and Lesko, LJ. Lack of In Vivo/In Vitro Correlations for 50mg and 250mg Primidone Tablets, Pharm. Res. 15:1085-1089 (1998).
98. Chen, Y, McCall, T, Baichwal, AR and Meyer, MC. The Application of an Artificial Neural Network and pharmacokinetic Simulations in the Design of Controlled-Release Dosage Forms. J. of Controlled Release, 59:33-41(1999).
99. Dalton, JD, Meyer, MC and Golub, AL. Pharmacokinetics of Aminolevulinic Acid after Oral and Intravenous Administration in Dogs. Drug Metabolism and Disposition. 27:432-435 (1999).
100. Beyssac E, Touaref F, Meyer MC, Jacob L, Sandopuk P and Aiache JM. Bioavailability of Morphine after administration of a new bioadhesive buccal tablet, Biopharm Drug Dispos. 19:401-405 (1998).
101. Dalton, JT, Zhou, D, Mukherjee, A, Young, D, Tolley, EA, Golub, AL and Meyer, MC. Pharmacokinetics of Aminolevulinic Acid and Intravesical Administration to Dogs. Pharm. Res., 16:288-295 (1999)
102. Kidd RS, Straughn AB, Meyer MC, Goldstein JA and Dalton JD. Pharmacokinetics

- of Chlorpheniramine, Phenytoin, Glipizide and Nifedipine in an Individual Homozygous for the CYP2C9*3 Allele. *Pharmacogenetics*, 9:71-80 (1999).
103. Meibohm, B, Zhang, Z, Beierle, I, Meyer, M. Epistaxis Associated with Elevation of INR in a Patient Switched to Generic Warfarin - Another View. *Pharmacotherapy* 20:866-869 (2000)
 104. Meyer, MC, Jarvi, EJ, Straughn, AB, Pelsor, FR, Williams, RL and Shah, VP, Bioequivalence of Immediate-release Theophylline Capsules, *Biopharm. Drug Dispos.* 20, 417-419 (1999)
 105. Meyer, MC, Straughn, AB, Jarvi, EJ, Patrick, KS, Pelsor, FR, Williams, RL, Patnaik, R, Chen, ML and Shah, VP, Bioequivalence of Methylphenidate Immediate-Release Tablets Using a Replicated Study Design to Characterize Intrasubject Variability, *Pharm. Res.* 17, 381-384 (2000)
 106. Meyer, MC. "United States Food and Drug Administration Requirements for Approval of Generic Drug Products, *J. Clin. Psychiatry CNS Capsules*, Volume 2, Issue 4, November 15, 2000 61: (2000)
 107. Meyer, MC, Straughn, AB, Mhatre, RM, Hussain, A, Shah,VP, Bottom, CB, Cole, ET, Lasko, LL, Mallinowshi, and Williams, RL. The Effect of Gelatin Cross-Linking on the Bioequivalence of Hard and Soft Gelatin Acetaminophen Capsules, *Pharm.Res.* 17:962-966 (2000)
 108. Veng-Pedersen P, Gobburu JV, Meyer MC and Straughn AB. Carbamazepine Level-A In Vivo-In-Vitro Correlation (IVIVC): A Scaled Convolution Based Predictive Approach. *Biopharm.Drug Dispos.* 21:1-6 (2000).
 109. Meyer, MC, Straughn, AB, Mhatre, RM, Shah, VP, Chen, ML, Williams, RL and Lesko, LJ. Variability in the Bioavailability of Phenytoin Capsules in Males and Females. *Pharm. Res.* 18:394-397 (2001).
 110. Meyer, MC. United States Food and Drug Administration Requirements for Approval of Generic Drug Products. *J. Clin. Psychiatry.* 62: 4-9, Supplement 5 (2001)
 111. Meyer, MC, Yacobi, I and Shah, VP. Similarities and Differences Among Various Regulatory Guidances for Bioequivalence Studies. Amidon, GL, Lesko, LJ, Midha, K and Shah, VP eds. *AAPS Press*, Alexandria, VA. 2001. In Review.
 112. Dalton JT, Yates CR, Yin D, Straughn A, Marcus SL, Golub AL, Meyer MC Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer.. *J Pharmacol Exp Ther.* 301:507-1 (2002).